Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Plumb

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Pharmacoeconomics|March 21, 2000
Annual cost of erectile dysfunction to UK SocietyJ M Plumb, J F Guest
Occupational Medicine (Philadelphia, Pa.)|May 20, 1998
An overview of workers' compensationJ M Plumb, J W Cowell
Pharmacoeconomics|January 11, 2001
Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UKJ M Plumb, J F Guest
International Journal of Laboratory Hematology|November 26, 2009
How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic reviewS Chambers, S Chadda, J M Plumb
Current Medical Research and Opinion|April 12, 2008
Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literatureG Dolan, L A Smith, S Collins, et al.
Thrombosis and Haemostasis|September 9, 2011
Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patientsA M Gallagher, E Setakis, J M Plumb, et al.
Current Medical Research and Opinion|September 26, 2008
Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 yearsS E Wolowacz, N Hess, V K Brennan, et al.
Thrombosis and Haemostasis|March 25, 2011
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspectiveS V Sorensen, A R Kansal, S Connolly, et al.
Thrombosis and Haemostasis|December 22, 2009
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacementS E Wolowacz, N S Roskell, J M Plumb, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmacoeconomics|March 21, 2000
Annual cost of erectile dysfunction to UK SocietyJ M Plumb, J F Guest
Occupational Medicine (Philadelphia, Pa.)|May 20, 1998
An overview of workers' compensationJ M Plumb, J W Cowell
Pharmacoeconomics|January 11, 2001
Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UKJ M Plumb, J F Guest
International Journal of Laboratory Hematology|November 26, 2009
How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic reviewS Chambers, S Chadda, J M Plumb
Current Medical Research and Opinion|April 12, 2008
Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and meta-analysis of the literatureG Dolan, L A Smith, S Collins, et al.
Thrombosis and Haemostasis|September 9, 2011
Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patientsA M Gallagher, E Setakis, J M Plumb, et al.
Current Medical Research and Opinion|September 26, 2008
Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: the evolving application of health economic modelling over 20 yearsS E Wolowacz, N Hess, V K Brennan, et al.
Thrombosis and Haemostasis|March 25, 2011
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspectiveS V Sorensen, A R Kansal, S Connolly, et al.
Thrombosis and Haemostasis|December 22, 2009
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacementS E Wolowacz, N S Roskell, J M Plumb, et al.
Pageof 1